In a step toward disease-modifying therapy, Tufts researchers and collaborators have pioneered nanoparticles that target damaged cartilage and adapt to disease severity.
Scientists discover that Candida albicans, overly abundant in people with alcohol use disorder, triggers immune response that alters dopamine signaling in mice.